2 May 2025 • Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) therapy significantly reduced the risks of major adverse cardiac and cerebrovascular events (MACCE), non-occlusive ischemic events (NACE), all-cause mortality, and revascularization without increasing bleeding risks.

Patients on PCSK9i had a reduced risk of NACE (aHR: 0.674), MACCE (aHR: 0.674), and all-cause death (aHR: 0.501). The matched win ratio analysis strongly favored PCSK9i (0.634).

This study fills a critical knowledge gap in understanding the combined use of PCSK9i and antiplatelet therapy for reducing ischemic events without compromising safety.

Source: International Journal of Cardiology | Read Full Story